The MAJESTY phase III study in primary membranous nephropathy met its primary endpoint, demonstrating Gazyva/Gazyvaro achieved complete remission at two years. This marks a significant advancement as up to 30% of patients with this condition progress to kidney failure. Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody, has shown promise in various autoimmune and kidney diseases. The study found Gazyva/Gazyvaro superior to tacrolimus in achieving complete remission. Furthermore, it demonstrated clinical benefits in overall remission and earlier complete remission rates. These positive results could lead to Gazyva/Gazyvaro becoming the first approved treatment specifically for primary membranous nephropathy. Primary membranous nephropathy is a serious autoimmune condition affecting kidney function and potentially leading to kidney failure. Achieving complete remission is crucial for preserving kidney function and preventing severe complications. The MAJESTY study's findings will be presented to health authorities for potential approval. This represents Roche's ongoing commitment to developing innovative treatments for kidney-related diseases.